| ￥3500 | |
| Z04183 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per ug by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CD28H/IGPR-1, His, Human at 5μg/ml (100μl/well) on the plate can bind Human B7H7, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 15.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 42-52 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized CD28H/IGPR-1, His, Human, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for Human B7-H7, hFc Tag with the EC50 of 73.8 ng/ml determined by ELISA. »
The purity of CD28H/IGPR-1, His, Human is greater than 95% as determined by SEC-HPLC. »
CD28H/IGPR-1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H. |
| Synonyms | TMIGD2; IGPR1; IGPR-1; CD28H; TPC1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
